Event at a glance


4th Annual Regenerative Medicine and Longevity science Forum

The World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.


Tuesday 26 April


09:00 Welcome

Jade Osei-Tutu, Conference Director, LSX

Jade Osei-Tutu   


09:05 Opening Remarks

Chairman:
Stephen Helliwell, VP discovery biology, Rejuveron,

Stephen Helliwell, VP discovery biology, Rejuveron,   


09:10 Keynote Panel: Regenerative, Rejuvenate or Reprogram?

An in-depth discussion about the applying geroscience to regenerative and longevity research. Investigating how the deeper understanding of ageing biology can progress the next 10 years of stem cells and longevity therapeutics.

Speakers:
Thomas Rando
, Co-Founder, Fountain Therapeutics
Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Thomas Rando, Chief Scientific Officer, Fountain Therapeutics 300x   Georgina Ellison-Hughes   Nir Barzilai, Director, Einstein Institute for Aging Research 300x   

Moderator:
James Peyer,
CEO, Cambrian

James Peyer CEO Cambrian


09:55 Keynote Panel: The COVID-19 Impact

COVID-19, the disease caused by the coronavirus Sars-CoV-2, is most prevalent in older adults, causes more severe symptoms in this population and over 90% of deaths are in the over 65 year olds.

Gain insights into how COVID-19 has impacted on social issues and research data on ageing science, including describing how an aged immune system contributes to this increased morbidity and mortality in older adults and also discuss research into the long term consequences for immunity and overall health in COVID-19 survivors. Then discuss how any lesson learnt can be applied to improve healthspan going forward.

James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic
Janet Lord, Institute of Inflammation and Ageing, University of Birmingham
Kristen Fortney, Co-founder and Chief Executive Officer, BioAge Labs

James Kirkland, Professor of Physiology & Medicine, Mayo Clinic 300x   Janet Lord Institute of Inflammation and Ageing, University of Birmingham   Kristen Fortney, CEO & Co-Founder, Bioage Labs Inc

Moderator:
Joan Mannick, Co-Founder and CEO, Tornado Therapeutics

Joan Mannick, CMO, resTORbio

10:40 Morning Break


Longevity Therapeutics

Advancing mechanistic understanding


11:10 Presentation: Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease

Exploring three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases.

Jerry McLaughlin, CEO, Life Biosciences

Jerry McLaughlin,CEO, Life Biosciences


11:35 Presentation: Harnessing endogenous immune biology to ablate pathogenic senescent cells and treat disease

  • Identifying the endogenous immune mechanism for clearing senescent cells
  • Therapeutically harnessing the immune system to remove senescent cells in a disease state
  • Achieving therapeutically relevant endpoints and durable effects
  • A paradigm shift for systemically treating age related multi-morbidities
Robin Mansukhani, CEO, Deciduous Therapeutics

Robin Mansukhani, CEO, Deciduous Therapeutics Inc


12:00 Presentation: Data-informed drug discovery and clinical development for therapies that target aging

BioAge’s AI-based platform analyzes human aging to discover key longevity mechanisms, and then targets these pathways with drugs aimed at age-related conditions with clear regulatory strategies and well-defined patient populations. We will describe our human data–driven platform and the three mechanistically diverse clinical-stage programs it has inspired to date.

Kristen Fortney, Co-founder and Chief Executive Officer, BioAge Labs

Kristen Fortney, CEO & Co-Founder, Bioage Labs Inc

 


Regenerative Medicine Track

Innovative technologies and mechanistic understanding


Chairwoman
Lynne Cox,
PI Lab of Ageing and Cell Senescence, University of Oxford

Lynne Cox, PI Lab of Ageing and Cell Senescence, University of Oxford


11:10 Presentation: Understanding the role of cell senescence and homeostasis in targeting cardiac regeneration

Mammalian ageing is defined as a gradual loss of the capacity to maintain tissue homeostasis or to repair tissues after injury/stress. The adult heart is considered a post-mitotic organ, having a low cardiomyocyte turnover rate over the course of human lifespan, which decreases further with ageing.

Like other tissues and organs senescent cells accumulate in the heart with ageing and in chronic disease, contributing to pathophysiology and deterioration. Regulation of cell senescence will impact the efficacy of regenerative therapies, especially if the majority of patients in need of it are of advanced age as occurs with heart disease and failure.

Targeting cell senescence using senolytics can rejuvenate the aged hearts regenerative capacity.

Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London

Georgina Ellison-Hughes


11:35 Presentation: Exploring the novel molecular mechanisms within the brain targeting Alzheimer’s disease that can be translated to the clinic

Examine how the relationship between cellular senescence and the chronic neurodegenerative diseases, including the mechanism around tau toxicities, impacts cellular senescence in the brain.

Miranda Orr, Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest School of Medicine

Miranda Orr


12:00 Presentation: Reframing Health and Aging through the Lens of Reproductive Longevity

Ovarian aging is perhaps the most promising but overlooked area in aging science. Understanding why ovaries age prematurely may provide important clues about aging in the rest of the body; ovaries also represent an elusive human model to test longevity interventions on a relatively short timescale.

Reproductive aging is about far more than fertility or menopause and impacts a woman’s entire life experience: career, family, health and well-being – this is about equality. In this presentation we will discuss a global movement to advance scientific research focused on reproductive longevity to accelerate the pace of discovery toward useful therapies.

Jennifer Garrison, Co-Founder & Director, Global Consortium for Reproductive Longevity & Equality, and Assistant Professor, Buck Institute

Jennifer Garrison, Assistant Professor, Buck Institute for Research on Aging

 


12:25 Lunch


 

13:40 Panel: Target Ageing Beyond the Therapeutic

How is important is diet, sleep, stress, exercise, and genetics for ageing and treating chronic diseases approach? Is a low caloric diet essential? Explore recent findings around the data the impact stress and sleep have on the biological age.

Speakers:
Grace McNamara, Chief Executive Officer, EXi
Elena Gross,
CEO/CSO and founder, KetoSwiss AG

  Grace McNamara, CEO, Exi 300x    Elena Gross, CEOCSO and founder, KetoSwiss AG

Moderator:
Tina Woods,
CEO, Collider Health

 Tina Woods, Founder & CEO, Collider Health 300x


14:15 Presentation: Building and investing in longevity companies

Explore how company builder Maximon, identifies the most promising business opportunities in the field of longevity and builds companies from scratch. Learn about its proven structures, financing, and a unique and inspiring playground for entrepreneurs to build a longevity venture.

Tobias Reichmuth, Partner and Co-Founder, Maximon

Tobias Reichmuth Co-Founder at Maximon


14:25 Panel: De-risking ageing drug development

The right early-stage data is crucial to move beyond the concept stage and secure investment.

Review the tools that can accurately assess how well lead compounds slow down the process of ageing within early-stage research. Identify the key data for longevity drug discovery and address the hurdles to obtain the data.

Speakers:
David Weinkove
, Co-Founder & CEO, Magnitude Biosciences
Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals
Patrick Burgermeister, Partner, Kizoo TechnologyCapital
Joan Mannick,
Co-Founder & CEO, Tornado Therapeutics

David Weinkove    Tea Shavlakadze, Director, Regeneron Pharmaceuticals Inc    Patrick Burgermesiter    Joan Mannick, CMO, resTORbio

Moderator:
Phil Newman,
CEO, Longevity Technology

  Phil Newman, CEO, Longevity Technology   


15:05 Presentation: Longevity Ecosystem- Challenges and opportunities about building a full longevity indication

We, at the Longevity tech Fund are building a longevity ecosystem that addresses the needs of the longevity vertical as a whole rather than providing standalone solutions

Jyothi Devakumar, Chief Science Officer and Partner, Longevity Tech Fund

Jyothi Devakumar, Longevity Tech Fund

 

13:40 Presentation: Advancing aging frailty through the clinic with ageing clinical endpoints.

Hear the latest data in the advanced 150 patient enrolled trial targeting ageing frailty. Discover ageing biomarkers and clinical endpoints used for an aged, focused indication.

Explore whether the phase II trial with Lomecel-B is positive in reducing inflammation and improving physical function.

Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron

Joshua Hare


14:05 Presentation: The role of Thermobalancing Therapy in extending healthspan in people with chronic diseases

Explore the essence of Thermobalancing Therapy and wearable Dr Allen's Devices as a novel and patented therapeutic treatment for different chronic health conditions, including kidney stone disease, benign prostate enlargement, chronic prostatitis, and back pain.

Discuss the impact of this safe non-invasive therapy on healthspan. Review data from 4 clinical trials and multiple patient case studies generated during 12-year long empirical observations.

Ariana Adjani, Co-founder, Fine Treatment

Ariana Adjani, Co-Founder, Fine Treatment


14.30 Presentation: A topical approach to reduce senescent cell accumulation in skin, our largest organ,  to improve skin health markers and overall longevity

Cellular senescence is known to play a role in age-related skin function deterioration, justifying the need for the development of senotherapeutic approaches to extend skin health and prevent age-related skin disorders. OneSkin has developed a comprehensive platform to screen senotherapeutic peptides and validate its role in reducing skin biological aging and improve skin health markers in vitro and in clinical studies. The understanding of these and other events that influence skin aging and function are now paving the way for elucidating the impacts of age-related skin deterioration on overall organismal health.

Carolina Reis Oliveira, Founder and Chief Executive Officer, OneSkin

Carolina Reis Oliveira, Founder and Chief Executive Officer, OneSkin


14:55 Genflow Biosciences: Could Gene Variant Found in Centenarians Boost Efforts to Develop Anti-aging Therapies?

Eric Leire, Co-founder & COO, BioAge

Eric Leire, CEO Genflow Biosciences

 


15:15 Afternoon Break


15:45 Panel: Translating and commercialising regenerative medicine and ageing science into therapeutics and consumer products

Assessing the route to market options by developing biologic or medical device designation. How do they differ in IP potential and market access parameters (pricing and reimbursement strategies)?

How important is buy in from big Pharma critical for commercialisation for regenerative products over companies establishing themselves as ‘big’ biopharma. Discussing how the advancements of regenerative medicine to translate real world interventions can be applied to longevity therapeutics and gain more interest from larger player and payers.

And assessing the market opportunities for rejuvenation applications that can be utilised direct-to-consumer such as wound management, skin care and dental care.

Ben Turner, Director - Venture Science, Eli Lilly and Company
Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron
Saranya Wyles, Assistant Professor of regenerative medicine and dermatologist, Mayo Clinic School of Medicine

Ben Turner Director- Venture Science, Europe Lilly New Ventures Corporate Business Development Eli Lilly and Company   Joshua Hare, Co-Founder & CSO, Longeveron LLC    Saranya Wylves   

Moderator:
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Nir Barzilai, Director,  Institute for Aging Research, Albert Einstein College of Medicine   


16:30 Roundtables

  • Commercial and market access strategies for regenerative medicine and longevity therapeutics
    Hosted by Mark Chalmers, Ernst & Young LLP
  • Company building, biotechnology operations
    Hosted by Juliette Han, Cambrian
  • Exploring the Hallmarks of Aging for druggable targets
    Hosted by Georg Terstappen, Cambrian
  • The right indication for drug development in longevity therapeutics 
    Hosted by Siham Ceballos, Bioartemis
  • Targeting aging muscle: preclinical models, novel targets, and clinical development strategies 
    Hosted by Justin Rebo, BioAge
  • Chronic disease management for healthspan extension and successful ageing
    Hosted by Ariana Adjani, Fine Treatment

Roundtable hosts:
Mark Chalmers
, Partner, Ernst & Young LLP
Juliette Han,
Chief Operating Officer, Cambrian
Georg Terstappen,
EVP, Drug Discovery, Cambrian
Siham Ceballos
, Founder and Managing Partner, Bioartemis
Justin Rebo, SVP Translational Aging Biology, BioAge
Ariana Adjani, Co-founder, Fine Treatment

Mark Chalmers, Partner, Ernst & Young LLP  Juliette Han, Ph.D., Chief Operating Officer, Cambrian    Georg C. Terstappen, Ph.D., EVP, Drug,Cambrian  Discovery   Siham Ceballos, Founder and Managing Partner, Bioartemis-1   Justin Rebo, SVP Translational Aging Biology, BioAge   Ariana Adjani, Co-Founder, Fine Treatment


17:45 Close of day 1 and Rejuvenate reception


 

Wednesday 27 April

 


09:00 Chair Opening Remarks

David Weinkove, Co-Founder & CEO, Magnitude Biosciences

David Weinkove, CEO, Magnitude Biosciences


09:05 Keynote Panel: Investment landscape within Regenerative medicine and Longevity Therapeutics

Removing the taboo of longevity and regenerative medicine within traditional biotech investment dynamics. Understand how the landscape is changing with new investment providers and deep dive into their due diligence process.

Alexandra Bause, Investor Director, Apollo Ventures
Ronjon Nag, Managing Director and Founder, R42 Group
Tobias Reichmuth,
Co-Founder, Maximon
Petr Sramek, Managing Partner, Longevity Tech Fund

Alexandra Bause, Co-Founder, Investment Director & Head of VentureLabs, Apollo Health Ventures   Ronjon Nag, Managing Director & Founder, R42 Institute 300x   Tobias Reichmuth Co-Founder at Maximon   Petr Sramek, Managing Partner, Longevity Tech Fund

Moderator
Jennifer Garrison, Co-Founder & Director, Global Consortium for Reproductive Longevity & Equality, and Assistant Professor, Buck Institute

Jennifer Garrison, Assistant Professor, Buck Institute for Research on Aging


09:50 Fireside Chat: Rejuveron’s outlook on the next decade opportunity for aging science

A fireside chat with Rejuveron’s CEO, Matthias Steger who will share his thoughts on where he sees interesting approaches within longevity therapeutics and how Rejuveron are working with emerging biotechs to progress their science to clinical stages and commercial entities.

Matthias Steger, Chief Executive Officer, Rejuveron

Matthias Steger, CEO of Rejuveron      

Moderator:
Jerry McLaughlin
, CEO, Life Biosciences

Jerry McLaughlin,CEO, Life Biosciences      


10:20 Panel: Commercialising skin with hard data

Skin, the largest organ, has seen commercial success in rejuvenation, particularly in Aesthetics and Cosmetics. But robust clinical data for dermatology is scrutinised. How much is the consumer is driving the market, is there enough data to back up the demand clinically? And what can be done to address the gaps? Hear about the innovative companies and technology the cosmetic and consumer market leaders are reviewing to back robust clinically proven research.

Sibylle Jager, Scientific Directorate Manager, L’Oréal
Stephanie Manson-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie
Cristiana Banila, Chief Scientific Officer, MITRA BIO

Sibylle Jager, Scientific Directorate Manager, LOREAL   Stephanie Manson Brown, Head of Clinical Development, Allergan 300x   Cristiana Banila, Chief Scientific Officer, MITRA Biotech

Moderator:
Carolina Reis Oliveira, Founder and Chief Executive Officer, OneSkin

Carolina de Oliveira, Founder and Chief Executive Officer, OneSkin


11:00 Morning Break


Ageing science: moving to the clinic


11:30 Panel: Challenges in clinical trials for longevity therapeutics

What are some common obstacles to clinical trials of longevity-based therapeutics — and what are the strategies that might be used to successfully overcome them? The panelists will discuss the challenge of indication selection, including an assessment of the decision process in previous p53 and mTOR longevity trials; the development of clinical tools for aging, including biomarkers and endpoints; navigating existing regulatory frameworks; and the impact (and value) of clinical trial “failures” as the field moves forward. 


Joan Mannick, Co-Founder and CEO, Tornado Therapeutics
Jimmy El Hokayem
, Programme Director, BioRasi
Jamie Dananberg, Chief Medical Officer, UNITY Biotechnology

Joan Mannick, CMO, resTORbio     Jimmy El Hokayem, Programme Director, BioRasi   Jamie Dananberg, Chief Medical Officer (CMO), Unity Biotechnology   

Moderator:
Eric Morgen
, CMO & COO, BioAge

Eric Morgen, CMO & COO, BioAge Labs


12:10 Presentation: Targeting Aging with Metformin (TAME): A Concrete Plan to Pave the Way for Targeting Aging

  • Is animal aging really relevant to human aging? We have studied the exome sequencing of 500 centenarians and 500 controls, all from in the DNA of the homogenous population of Ashkenazi Jews, and using a system biology approach asked what are the pathways that are district for exceptional longevity. We discovered that alterations in centenarians included the insulin/IGF-1 signaling, mTOR pathways and other pathways that suggest that human aging and longevity are conserved through evolution and pose targets for therapy.

  • Can we establish criteria for biological aging that will change with therapies that will target aging? I will demonstrate how we discovered, by looking at 5000 protein levels (by Aftamers) in 1000 subjects between ages 65-95, the fingerprint of biological vs, chronological aging.

  • Can we change the regulatory establishment to recognize aging as a target for preventing age-related diseases? I will talk about the rational for study that is about to be launched, Targeting Aging with Metformin (TAME). Metformin is ‘tool’ to pave the way for the FDA to show that targeting aging will prevent age-related diseases.
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Nir Barzilai, Director,  Institute for Aging Research, Albert Einstein College of Medicine   


12:35 Presentation: Macular degeneration clinical development via targeting BCL pathways

Explore ocular biology around the senescent triggers of disease and targeting the BCL-xL pathway as a senolytic mechanism. Discuss the lead compound through the clinic including early phase results.

Jamie Dananberg, Chief Medical Officer, UNITY Biotechnology

Jamie Danaberg, Chief Medical Officer, UNITY Biotechnology


13:00 Lunch


14:15 Fireside Chat: Tackling Immunogenicity in gene therapy, cell therapy and organ transplantation

Discussing the triggers of allogenic graft rejection, the mechanistic understanding of immunogenicity and importance when developing cell and gene therapy.

Stefan Tullius, Professor of Surgery, Transplant Surgery, Harvard Medical School

Stefan Tullius  

Moderator:
Michael Hufford
, Co-Founder and CEO, Lygenesis

Michael Hufford, Co-Founder and CEO, Lygenesis


14:40 Pre-clinical development of new senotherapeutics via modulation of RNA splicing

  • Regulated mRNA processing is achieved by the combinatorial action of splicing factors; proteins which activate or inhibit splice site choice.
  • Splicing factor expression declines during ageing because of constitutive and unresolved cellular signalling, with is a provocation towards cellular senescence.
  • Treatment of senescent cells with small molecules or targeted oligonucleotide interventions designed to restore splicing factor expression can ameliorate multiple features of senescence in human primary skin cells.
  • Dysregulation of mRNA splicing may represent a new (and druggable) driver of cellular ageing, which can be targeted to treat the causes, rather than the consequences, of cellular ageing.

Lorna Harries, Chief Scientific Officer, Senisca

Lorna Harries, Professor, University of Exeter 300x-1


15:05 Presentation: Targeting age-related pathways to treat aging disorders

  • Discuss construction of age-related gene expression signatures (AGES) to identify and target common age-related pathways that may create permissive or causative environment for disease.
  • AGES point to potential mechanisms that contribute to age-related disorders and can be used for therapeutic target discovery.
  • Discuss pre-clinical studies conducted in rats, targeting TORC1 (target of rapamycin complex 1) to modulate age-related pathways and morbidities.

Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals

  Tea Shavlakadze, Director, Regeneron Pharmaceuticals Inc   



15:30 Presentation: Lymphatic Bioreactors, Ectopic Organs, and the Commercialization of Regenerative Medicine

  • Lymph nodes’ natural, evolutionary-based purpose as part of our immune response system can be made to act as in vivo bioreactors for a variety of tissue types

  • Cell therapies engrafted into lymph nodes are capable of producing organogenesis – the generation to functional, therapeutic tissues to complement a native organ’s functioning

  • A translational medicine program has enabled this technology to move from the lab to the clinic, with a first application in patients with end stage liver disease

  • The commercial advantages and disadvantages of an allogeneic cell source with low COGS will be discussed
Michael Hufford, Co-Founder and CEO, Lygenesis

Michael Hufford, Co-Founder and CEO, Lygenesis


15:55 Closing Remarks


16:00 Congress Closes

 

DOWNLOAD BROCHURE